Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets (Unaudited)

v3.22.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 101,669 $ 106,084
Short-term investments 200,142 264,984
Restricted cash 146 194
Accounts receivable 668 986
Prepaid expenses and other current assets 11,574 12,373
Assets held for sale 190  
Total current assets 314,389 384,621
Property and equipment, net 9,109 53,780
Operating lease assets 18,933 26,159
Restricted cash - long-term 1,200 1,200
Other assets 2,220 2,367
Long-term assets held for sale 51,429  
Total assets 397,280 468,127
Current liabilities:    
Accounts payable 11,945 17,368
Accrued compensation 16,381 25,150
Accrued research and development expenses 13,990 13,451
Deferred revenue 50,943 40,760
Other current liabilities 8,051 9,057
Liabilities held for sale 252  
Total current liabilities 101,562 105,786
Deferred revenue - long-term 45,000 55,708
Operating lease liabilities - long-term 17,453 25,518
Other long-term liabilities 616 1,501
Long-term liabilities held for sale 8,333  
Total liabilities 172,964 188,513
Commitments and contingencies (Note 8)
Stockholders’ equity:    
Common stock—$0.0001 par value, 500,000 shares authorized as of March 31, 2022 and December 31, 2021; 93,406 and 91,671 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively 9 9
Additional paid-in capital 1,779,026 1,744,695
Accumulated other comprehensive (loss) income (1,892) (368)
Accumulated deficit (1,552,827) (1,464,722)
Total stockholders’ equity 224,316 279,614
Total liabilities and stockholders’ equity $ 397,280 $ 468,127